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SUMMARY
Circulating levels of thegutmicrobe-derivedmetabo-
lite trimethylamine-N-oxide (TMAO) have recently
been linked to cardiovascular disease (CVD) risk.
Here,weperformed transcriptional profiling inmouse
models of altered reverse cholesterol transport (RCT)
and serendipitously identified the TMAO-generating
enzyme flavin monooxygenase 3 (FMO3) as a power-
ful modifier of cholesterol metabolism and RCT.
Knockdown of FMO3 in cholesterol-fed mice alters
biliary lipid secretion, blunts intestinal cholesterol
absorption, and limits the production of hepatic
oxysterols and cholesteryl esters. Furthermore,
FMO3 knockdown stimulates basal and liver X
receptor (LXR)-stimulatedmacrophageRCT, thereby
improving cholesterol balance. Conversely, FMO3
knockdown exacerbates hepatic endoplasmic retic-
ulum (ER) stress and inflammation in part by
decreasing hepatic oxysterol levels and subsequent
LXR activation. FMO3 is thus identified as a central
integrator of hepatic cholesterol and triacylglycerol
metabolism, inflammation, and ER stress. These
studies suggest that the gut microbiota-driven
TMA/FMO3/TMAO pathway is a key regulator of lipid
metabolism and inflammation.
INTRODUCTION
Atherosclerosis and associated cardiovascular disease (CVD)
remain the largest causes of mortality in developed countries
(Go et al., 2013). Despite widespread use of statins, CVD-asso-
ciatedmortality andmorbidity have been reduced by only30%
(Go et al., 2013), demonstrating a clear need for better therapeu-
tic strategies. Elevation of high-density lipoprotein (HDL) func-
tion is thought to be an attractive therapeutic strategy (Rader
and Tall, 2012). However, recent clinical trials (Boden et al.,
2011; Schwartz et al., 2012) and Mendelian randomization
studies (Voight et al., 2012) have failed to show clinical benefits
of HDL cholesterol elevation, calling into question the role of
HDL cholesterol as a surrogatemarker of protection from athero-
sclerosis (Rader and Tall, 2012). Both proponents and critics
alike of the ‘‘HDL hypothesis’’ agree on one thing: further studies
are needed to understand the mechanism regulating the funda-
mental process of HDL-driven reverse cholesterol transport
(RCT). The prevailing model for RCT is that cholesterol from
the artery wall is delivered to the liver via HDL, from where it is
then secreted into bile before leaving the body through the feces
(Dietschy and Turley, 2002; Rader et al., 2009; Rosenson et al.,
2012). However, we and others have recently demonstrated
that RCT can also proceed through a nonbiliary pathway known
as transintestinal cholesterol excretion (TICE), which persists in
both the surgical or genetic absence of biliary cholesterol secre-
tion (Temel et al., 2010; Temel and Brown, 2012; Brown et al.,
2008; Le May et al., 2013; van der Velde et al., 2007; van der
Veen et al., 2009). Under normal physiologic conditions the hep-
atobiliary route predominates and TICE is a minor pathway, only
contributing30% of the total cholesterol lost through the feces
in mice (Temel and Brown, 2012). However, pharmacologic
activation of liver X receptor (LXR) can preferentially stimulate
the nonbiliary pathway to where TICE contributes greater than
60% of the total cholesterol lost through the feces (van der
Veen et al., 2009). Although mechanisms regulating the classic
hepatobiliary pathway of RCT have been well defined (Yu
et al., 2002; Graf et al., 2003; Groen et al., 2008; Wiersma
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et al., 2009; Temel et al., 2007), almost no mechanistic informa-
tion exists for the nonbiliary TICE pathway (Temel and Brown,
2012; Brufau et al., 2011).
We have previously described several mouse models where
the nonbiliary TICE pathway is either chronically (Temel et al.,
2010) or acutely stimulated (Marshall et al., 2014). Here, we
have taken advantage of these mouse models as hypothesis-
generating tools. To identify regulators of TICE and RCT, we per-
formed transcriptional profiling in NPC1L1-liver-transgenic mice
(which exhibit chronic TICE stimulation; Temel et al., 2010) and
second generation acyl-coenzyme A: cholesterol acyltransfer-
ase 2 (ACAT2) antisense oligonucleotide (ASO)-treated mice
(which exhibit acute TICE stimulation; Marshall et al., 2014).
From this screening, we found that the hepatic expression of
flavin-containing monooxygenase 3 (FMO3) was coordinately
downregulated in mouse models of stimulated TICE. In parallel,
independent studies have shown that plasma levels of FMO30s
product trimethylamine-N-oxide (TMAO) are highly predictive
of atherosclerosis in humans, and TMAO is proatherogenic in
mice (Wang et al., 2011; Wang et al., 2014; Tang et al., 2013;
Koeth et al., 2013; Bennett et al., 2013; Brown and Hazen
2014). Additionally, we have recently shown that dietary supple-
mentation with the FMO3 product TMAO inhibits macrophage
RCT in vivo (Koeth et al., 2013). Here we follow up on these col-
lective observations, and demonstrate that FMO3 knockdown
stimulates non-biliary macrophage RCT and reorganizes whole
body cholesterol balance. The current studies have also uncov-
ered a previously unknown role for FMO3 in regulating hepatic
LXR signaling, which controls endoplasmic reticulum (ER) stress
and inflammation. Collectively, these observations identify the
gut microbiota-driven TMA/FMO3/TMAO pathway as a key
integrator of lipid metabolism and immune cell function and spe-
cifically identify FMO3 as a key regulator of sterol balance and
RCT, independent of its role in TMAO production. Given that
this pathway has now been identified in two separate screens
(work described here and metabolomics screening by Wang
et al., 2011), we believe this pathway represents a central regu-
latory node for CVD pathogenesis.
RESULTS
Transcriptional Profiling Identifies FMO3 as a Regulator
of RCT
To identify potential regulators of macrophage RCT, we per-
formed microarray analysis in liver from two independent mouse
models where TICE was either chronically (NPC1L1-liver-trans-
genic mice; Temel et al., 2010) or acutely (ACAT2 ASO treat-
ment; Marshall et al., 2014) stimulated. With a stringent
threshold (p < 0.001) set for differentially expressed genes
(DEGs), there were less than 100 DEGs within each array data
set (Figures 1A and 1B), and the vast majority of DEGs were
not coordinately regulated in both cohorts (Tables S1, S2, S3,
and S4). In fact, there were only two genes that were coordi-
nately regulated in both models of TICE augmentation (Figures
1C and 1D). The sole gene that was upregulated in both acute
and chronic TICE mouse models was Gm10567, which is pre-
dicted to be noncoding RNA of unknown biological function (Fig-
ure 1C). The only gene that was coordinately downregulated in
both TICE models was FMO3 (Figure 1D; Tables S1 and S2).
We subsequently utilized real-time PCR to confirm that FMO3
mRNA expression was significantly reduced in both acute
(ACAT2 ASO-treated) and chronic (NPC1L1-liver-transgenic
mice) TICE models (Figures 1E and 1F). Interestingly, FMO3
mRNA expression closely reflects the concentration of choles-
terol in bile, given that FMO3 expression is significantly reduced
in both NPC1L1-liver transgenic mice and in mice with dimin-
ished expression of the biliary cholesterol half transporter
ABCG8 (data not shown). Given that the FMO3 enzymatic prod-
uct TMAO has recently been associated with increased CVD risk
in humans and shown to both promote atherosclerosis and
inhibit RCT in mice (Wang et al., 2011; Tang et al., 2013; Koeth
et al., 2013; Bennett et al., 2013; Brown and Hazen, 2014), we
decided to further interrogate the primary role of FMO3 in
cholesterol balance and RCT.
ASO-Mediated Knockdown of FMO3 Reorganizes
Whole-Body Cholesterol Balance
To examine the role of FMO3 in cholesterol balance, we utilized
second-generation ASO targeting (Crooke, 1997) in mice fed
different levels of dietary cholesterol. FMO3 ASO treatment
very effectively reduced hepatic FMO3 mRNA (Figure 2A) and
protein (Figure 2B) expression, when compared to mice treated
with a nontargeting control ASO. As expected, FMO3 knock-
down significantly increased circulating levels of FMO3’s sub-
strate trimethylamine (TMA) (Figure 2C), while it reciprocally
decreased circulating levels of FMO3’s product TMAO (Fig-
ure 2D). In parallel, FMO3 knockdown resulted in significant ele-
vations of TMA and reciprocal decreases in TMAO in the liver
(data not shown). FMO3 knockdown did not alter the overall
health or growth of mice during the period of investigation
(data not shown), but it did result in a striking reorganization
of cholesterol balance. First, FMO3 knockdown significantly
reduced intestinal cholesterol absorption in mice fed a low-
cholesterol diet, and it more modestly decreased cholesterol
absorption in mice fed a high-cholesterol diet (Figure 2E). Corre-
sponding trends were seen in the mass amount of cholesterol
lost in feces, where FMO3 knockdown significantly increased
fecal neutral sterol loss in mice fed a low-cholesterol diet, but
the trend for increased fecal sterol loss failed to reach signifi-
cance in FMO3 ASO-treated mice fed a high-cholesterol diet
(Figure 2F). In both dietary conditions, FMO3 knockdown signif-
icantly reduced hepatic cholesteryl ester levels (Figure 2G).
However, hepatic free cholesterol levels were not altered by
diet or ASO treatment (Figure 2H). FMO3 knockdown also
reduced the biliary secretion of cholesterol (Figures 2I, S1A,
and S1B) and phospholipids (Figures S1E and S1F), without
dramatically altering biliary bile acid levels (Figures S1C and
S1D). FMO3 ASO-driven reductions in biliary phospholipid
were accompanied by significant reductions in the hepatic
expression of mdr2 (P-glycoprotein) (data not shown). Finally,
FMO3 knockdown did not dramatically alter plasma lipid levels
in low-cholesterol-fed mice, but it did cause a modest shift in
plasma cholesterol distribution in high-cholesterol-fedmice (Fig-
ures 2J–2P). In mice fed a high-cholesterol diet, FMO3 knock-
down significantly reduced very low-density lipoprotein (VLDL)
cholesterol levels (Figures 2L and 2M) while causing an elevation
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Figure 1. Transcriptional Profiling Defines FMO3 as a Regulator of RCT
(A) Microarray analysis in the acute TICE mouse model. Female C57BL/6 mice were treated with a nontargeting control ASO (Con. ASO) or an ASO targeting
ACAT2mRNA (A2 ASO) as previously described for 1week (Marshall et al., 2014). Differentially expressed genes (DEGs) are shown as a heatmap (all genes shown
have p < 0.001, n = 4).
(B) Microarray analysis in chronic TICEmousemodel. Female wild-type (WT) or NPC1L1-liver transgenic mice (NPC1L1Tg; Temel et al., 2010) were maintained on
a high-cholesterol diet (0.2%, w/w) for 8 weeks. Differentially expressed genes (DEGs) are shown as a heatmap (all genes shown have p < 0.001, n = 5).
(legend continued on next page)
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of low-density lipoprotein (LDL) cholesterol levels (Figures 2L
and 2N). In contrast, FMO3 knockdown did not alter levels of
HDL cholesterol (Figure 2O) or plasma triglycerides (TG)
(Figure 2P). Detergent block experiments demonstrated that
FMO3 knockdown does not alter VLDL-TG secretion but does
blunt VLDL-CE secretion significantly (data not shown). Finally,
FMO3 knockdown resulted in a significant reduction of the
total bile acid pool size (Figure S2A), which is likely driven by
diminished expression of the major bile acid synthetic enzymes
Cyp7a1 and Cyp8b1 (Figures S2B and S2C). Collectively,
these results show that FMO3 knockdown reorganizes
cholesterol balance in a diet-specificmanner, indicating amech-
anistic link between FMO3 and cholesterol and bile acid
metabolism.
FMO3 Coordinates Sterol-Sensing Transcription Factor
Activation in the Liver
Cellular cholesterol levels are carefully sensed and regulated by
at least two major transcriptional mechanisms involving sterol
regulatory element-binding proteins (SREBPs) and liver X recep-
tors (LXRs) (Tontonoz and Mangelsdorf, 2003; Brown and Gold-
stein, 1999). Interestingly, FMO3 knockdown results in reciprocal
regulation of the SREBP and LXR pathways in mouse liver (Fig-
ure 3) in a diet-specific manner. In mice fed a low cholesterol
diet, where endogenous cholesterol synthesis rates are high,
FMO3 knockdown caused significant elevation in SREBP2 target
genes including 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase (Figure 3J), HMG-CoA synthase (Figure 3K), and
squalene synthase (Figure 3L). In contrast, in mice fed a high-
cholesterol diet, where the liver is burdened with excess choles-
terol, FMO3 knockdown caused a marked reduction in LXR
target genes including ATP binding cassette transporters G5
(Figure 3A) and G8 (Figure 3B), lysophosphatidylcholine acyl-
transferase 3 (LPCAT3) (Figure 3D), SREBP1c (Figure 3F), fatty
acid synthase (Figure 3G), and stearoyl-CoA desaturase 1 (Fig-
ure 3H). However, LXR alpha and ATP binding cassette trans-
porter A1 (ABCA1) mRNA expression was not altered by FMO3
knockdown (Figures 3C and 3E). FMO3 ASO-driven alteration
in LXR signaling can likely be explained by reduced expression
of oxysterol synthetic enzymes Cyp27a1 and Cyp46a1 (data
not shown), resulting in decreased availability of endogenous
oxysterol ligands in the liver (Figures 3M–3R). Interestingly,
circulating oxysterol levels were not similarly altered by FMO3
knockdown, with the exception of the minor oxysterol 25-
hydroxycholesterol being slightly elevated (data not shown). In
agreement with dampened LXR signaling, FMO3 knockdown
strikingly decreased the expression of LXR target genes involved
in de novo lipogenesis, and it blunted hepatic steatosis (data not
shown). Collectively, these data suggest that FMO3 knockdown
depletes hepatic cholesterol stores to a level where SREBP2-
driven transcription is activated (Figures 3I–3L) and LXR
signaling is reciprocally repressed (Figures 3A–3H) due to dimin-
ished oxysterol abundance (Figures 3M–3R).
FMO3 Knockdown Stimulates Nonbiliary
Macrophage RCT
Given that FMO3 was coordinately downregulated in both acute
and chronic models of TICE (Figure 1), and because prior studies
showed TMAO-fed mice had significant reductions in macro-
phage RCT (Koeth et al., 2013), we wondered whether FMO3
might be linked mechanistically to biliary or nonbiliary RCT. In
our macrophage RCT studies, a subset of mice were treated
with the LXR agonist T0901317, since it is known that LXR acti-
vation promotes macrophage RCT primarily by augmenting the
nonbiliary TICE pathway (van der Veen et al., 2009). FMO3
knockdown very modestly decreased total plasma cholesterol
levels (Figure 4A). When treated with the LXR agonist
T0901317, both control ASO- and FMO3 ASO-treated mice
exhibited mild hypercholesterolemia, with the majority of the
cholesterol elevation seen in large HDL particles (data not
shown), as has been previously described (Grefhorst et al.,
2002). Following [3H]-cholesterol-labeled macrophage injection
into the peritoneal cavity, the plasma [3H]-cholesterol accumula-
tion was significantly lower in FMO3-inhibited mice, both in the
vehicle- and T0901317-treated groups (Figure 4B). This reduc-
tion in [3H]-cholesterol was largely due to a decrease in large
HDL particles (Figure 4C), which tracked closely with the choles-
terol mass distribution (data not shown). Importantly, in control
ASO-treated mice, there was an expected increase in LXR
agonist-inducible biliary [3H]-cholesterol secretion (Figure 4G).
In contrast, FMO3 ASO-treated mice had lower biliary [3H]-
cholesterol recovery, both in the vehicle- and T0901317-treated
groups, and lacked the expected LXR agonist-inducible
response for biliary cholesterol secretion (Figure 4G). Interest-
ingly, FMO3 ASO-treated mice also lack T0901317-induced
biliary [3H]-bile acid secretion (Figure 4H). Despite having
reduced levels of biliary [3H]-cholesterol (Figure 4G), FMO3
knockdown mice had increased basal and LXR agonist-stimu-
lated disposal of cholesterol into the feces, as measured by
both [3H]-cholesterol recovery (Figure 4D) andmass fecal neutral
sterol loss (Figure 4F). FMO3 knockdown also modestly
increased fecal [3H]-bile acid recovery in both basal and LXR-
stimulated conditions (Figure 4E). At the time of necropsy, the
hepatic recovery of macrophage-derived [3H]-cholesterol in the
form of [3H]-cholesterol (Figure 4I) and [3H]-bile acid (Figure 4J)
was not altered by FMO3 knockdown. Likewise, intestinal recov-
ery of macrophage derived [3H]-cholesterol in the form of [3H]-
cholesterol (Figure 4K) and [3H]-bile acid (Figure 4L) was not
altered by FMO3 knockdown, but there was a slight increase in
intestinal [3H]-cholesterol in mice treated with T0901317 (Fig-
ure 4K). Interestingly, LXR activation significantly represses he-
patic FMO3mRNA (Figure 4M) and protein (Figure 4N). However,
FMO3 knockdown did not dramatically alter canonical LXR-
driven target gene expression in the liver and small intestine in
these mice maintained on a low-cholesterol diet (data not
shown). Of particular relevance to RCT, FMO3 knockdown
significantly reduced intestinal NPC1L1 expression (Figure 4O),
(C) Venn diagram showing coordinately upregulated genes in both microarray data sets. The shared gene indicated is Gm10567 and is of unknown function.
(D) Venn diagram showing coordinately downregulated genes in both microarray data sets. The shared gene is FMO3.
(E) qPCR quantification of hepatic FMO3 mRNA levels in female control and ACAT2 ASO-treated mice (n = 5).
(F) qPCR quantification of hepatic FMO3 mRNA levels in female WT and NPC1L1-liver transgenic mice (NPC1L1Tg) (n = 5).
Cell Reports 10, 326–338, January 20, 2015 ª2015 The Authors 329
Figure 2. ASO-Mediated Knockdown of FMO3 Reorganizes Whole-Body Cholesterol Balance
Female C57BL/6 mice were fed either a low- (0.02%, w/w) or high-cholesterol (0.2%, w/w) diet and treated with either a control (nontargeting) ASO or an ASO
targeting FMO3 mRNA for 6 weeks.
(A) qPCR quantification of hepatic FMO3 mRNA levels.
(B) Western blot determination of FMO3 protein levels.
(C) Circulating levels of the FMO3 substrate trimethylamine (TMA).
(D) Circulating levels of the FMO3 product trimethylamine-N-oxide (TMAO).
(E) Fractional cholesterol absorption was determined using the dual fecal isotope method.
(F) Fecal neutral sterol excretion was determined by gas liquid chromatography.
(G) Hepatic cholesteryl ester (CE) levels.
(H) Hepatic free cholesterol (FC) levels.
(I) Biliary cholesterol secretion rate was measured following common bile duct cannulation.
(J) Total plasma cholesterol (TPC) levels.
(K) Cholesterol distribution of pooled plasma in mice fed a low-cholesterol diet (n = 5 per pool).
(L) Cholesterol distribution of pooled plasma in mice fed a high-cholesterol diet (n = 5 per pool).
(legend continued on next page)
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which is in agreement with alterations in intestinal cholesterol ab-
sorption (Figure 2E). Collectively, these results demonstrate that
FMO3 knockdown promotes both basal and LXR agonist-stimu-
lated macrophage RCT (Figure 4D and 4F) while repressing
biliary cholesterol levels (Figures 4G, S1A, and S1B) and intesti-
nal cholesterol absorption (Figure 2E).
FMO3 Knockdown Promotes Hepatic ER Stress and
Inflammation by Dampening LXR Activation
LXR activation has previously been shown to dampen both in-
flammatory responses and ER stress by upregulating direct
target genes, such as LPCAT3 (Rong et al., 2013), and transre-
pressing proinflammatory genes, such as iNOS and COX-2 (Jo-
seph et al., 2003). Given that oxysterol ligand availability is lower
in FMO3 knockdown mice, we hypothesized that this may pro-
mote hepatic inflammation and ER stress. Indeed, FMO3 knock-
down caused marked infiltration of macrophages into the liver
(Figures 5A and 5B) and increased the expression of macro-
phage-derived proinflammatory cytokines and chemokines (Fig-
ures 5C and 5D). Furthermore, FMO3 knockdown increased the
expression of several genes linked to ER stress (ATF3, CHOP)
(Figures 5C and 5D) and increased CHOP protein expression
(Figure 5E). FMO3 knockdown also increased the activation of
c-Src (Figure 5E), which has also recently been linked to satu-
rated fatty acid-induced ER stress and inflammatory signaling
(Holzer et al., 2011). Importantly, either providing endogenous
LXR agonists (i.e., feeding 0.2% cholesterol in the diet) or
providing an exogenous LXR agonist (T0901317) blunted
FMO3 ASO-driven hepatic inflammation (Figures 5B–5D), c-Src
activation (Figure 5E), and ER stress (Figures 5C–5E). Collec-
tively, these results suggest that FMO3 knockdown promotes
hepatic inflammation and ER stress in part by diminishing LXR
activity. Collectively, our results are consistent with hepatic
FMO3 serving as a critical determinant of the well-known ability
of LXR to reciprocally regulate lipid metabolism and inflamma-
tion (Joseph et al., 2003; Rong et al., 2013).
FMO3 Gain-of-Function Reciprocally Reorganizes
Cholesterol Balance and Hepatic Inflammation
To confirm the specificity of our results with ASO-mediated
knockdown of FMO3, we performed parallel gain-of-function
experiments by means of adenoviral-mediated gene delivery
(Figure S3). Administration of FMO3 adenovirus resulted in an
18-fold increase in hepatic FMO3mRNA levels (Figure S3A). He-
patic overexpression of FMO3 resulted in modest but significant
reductions in fecal neutral sterol loss (Figure S3B) while more
substantially increasing biliary cholesterol loss (Figure S3C).
Furthermore, FMO3 overexpression resulted in a20% increase
in total plasma cholesterol levels (Figure S3D). In further agree-
ment with loss-of-function data, FMO3 overexpression signifi-
cantly reduced the hepatic expression of genes involved in
inflammation (CD68, F4/80) and ER stress (ATF3) (Figures
S3E–S3G). FMO3 overexpression also increased expression of
the LXR target genes ABCA1 (Figure S3H) and LPCAT3 (Fig-
ure S3I). These data further support the notion that FMO3 is a
central regulator of cholesterol balance and hepatic inflamma-
tory responses, given that both gain and loss of function impacts
the same biochemical pathways.
FMO3 Knockdown Regulates Intestinal Cholesterol
Balance in a Gut Microbe-Dependent Fashion
FMO3 has many potential endogenous and xenobiotic sub-
strates (Cashman and Zhang, 2006; Cashman 2008) that could
be involved in its ability to regulate cholesterol balance
and inflammation. However, we know that the FMO3 substrate
TMA and product TMAO are generated solely from gut
microbe-dependent metabolism of dietary methylamine nutri-
ents (Wang et al., 2011; Koeth et al., 2013). To determine the
involvement of gut microbial metabolites in the ability of FMO3
ASOs to reorganize cholesterol balance and hepatic inflamma-
tion, we suppressed gut microbial communities using a poorly
absorbed cocktail of antibiotics. After only 1 week of treatment,
levels of both the FMO3 substrate TMA and its product TMAO
were barely detectable in antibiotic treated mice (Figures S4A
and S4B). Interestingly, antibiotic-mediated suppression of gut
microbes completely blocked the ability of FMO3 ASO treatment
to reduce intestinal cholesterol absorption (Figure S4C) and
elevate fecal neutral sterol loss (Figure S4D). However, antibiotic
treatment did not significantly alter the ability of FMO3 ASO
treatment to increase hepatic CD68 expression (Figure S4F),
decrease hepatic FAS expression (Figure S4G), or decrease he-
patic Cyp8b1 expression (Figure S4H). Collectively, these results
suggest that the ability of FMO3 ASO treatment to alter intestinal
cholesterol absorption and fecal neutral sterol excretion likely re-
lies on gutmicrobial metabolites, of which TMA is a strong candi-
date, but FMO3 ASO-driven effects on hepatic inflammation,
fatty acid synthesis, and bile acid synthesis likely arise from
another non-microbial source.
The Ability of FMO3 ASOs to Reorganize Lipid
Metabolism and Inflammation Does Not Arise from
Diminished TMAO Levels
Given that TMAO has been linked to CVD risk and FMO3 ASO
treatment reduces TMAO levels in the circulation and liver (Fig-
ure 2D, data not shown), we wanted to determine the involve-
ment of TMAO in the lipid and inflammatory phenotypes seen
with FMO3 knockdown. To achieve this, we provided TMAO as
a dietary supplement in control and FMO3 ASO-treated mice.
As expected, FMO3 knockdown reduced circulating TMAO
levels, but dietary TMAO supplementation effectively blocked
this effect (Figure S4J). Surprisingly, dietary TMAO supplemen-
tation in FMO3-inhibitedmice resulted in amarked accumulation
of plasma TMA (80-fold above control levels), likely arising from
bacterial conversion of TMAO to TMA (Ansaldi et al., 2007)
(M) Very low-density lipoprotein cholesterol (VLDLc) levels.
(N) Low-density lipoprotein cholesterol (LDLc) levels.
(O) High-density lipoprotein cholesterol (HDLc) levels.
(P) Total plasma triglyceride (TG) levels.
All data represent the mean ± SEM from five to ten mice per group. *Significantly different from the control ASO group within each diet group (p < 0.05).
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Figure 3. FMO3 Coordinates Sterol-Sensing Transcription Factor Activation in the Liver
Female C57BL/6 mice were fed either a low- (0.02%, w/w) or high-cholesterol (0.2%, w/w) diet and treated with either a control (nontargeting) ASO or an ASO
targeting FMO3 mRNA for 6 weeks.
(A–H) Expression of LXR and downstream target genes in the liver.
(I–L) Expression of SREBP2 and downstream target genes in the liver.
(M–R) Hepatic levels of oxysterols
All data represent the mean ± SEM from four to five mice per group. *Significantly different from the control ASO group within each diet group (p < 0.05).
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coupled with diminished hepatic conversion of TMA into TMAO
by FMO3. Despite the ability of dietary TMAO to rescue circu-
lating plasma TMAO levels in FMO3 ASO-treated mice (Fig-
ure S4J), this did not alter the ability of FMO3 ASO treatment
to alter cholesterol balance (Figures S4K and S4L) or hepatic
gene expression (Figures S4M–S4P). Interestingly, in this
TMAO add-back experiment, the levels of circulating TMA are
positively correlated (R2 = 0 0.45, p < 0.0001) with the amount
of fecal neutral sterol loss (data not shown), indicating a potential
role for TMA as a gut microbe-derived signal regulating choles-
terol balance. Collectively, these data strongly suggest that
although chronic elevation of TMAO can be proatherogenic
(Wang et al., 2011, Koeth et al., 2013), TMAO is not likely involved
in the ability of FMO3 inhibitors to reorganize cholesterol balance
and hepatic inflammation.
DISCUSSION
Now identified in two independent screens of altered RCT or
CVD risk (Figure 1; Wang et al., 2011), the gut microbe-driven
TMA/FMO3/TMAO pathway is increasingly being pursued for
the treatment or prevention of CVD. However, this pathway ex-
hibits many levels of complexity including dietary inputs (Wang
et al., 2011; Koeth et al., 2013), requirement of bacterial
metabolism (Brown and Hazen, 2014), and complex hormonal
regulation of the FMO enzyme family (Bennett et al., 2013).
Furthermore, TMAO feeding (Wang et al., 2011; Koeth et al.,
2013) and FMO3 knockdown (data shown here) exert some
consistent but many divergent effects on cholesterol and bile
acid metabolism across multiple tissues (Figure S5). Although
FMO3 and TMAO are directly biochemically connected, our
studies suggest that the FMO3 enzyme and the TMAO product
likely impact lipid metabolism and inflammation through distinct
mechanisms. Therefore it will become increasingly important to
differentiate the ability of FMO3 itself versus TMAO to alter the
pathogenesis of CVD. The major findings of the current study
include the following: (1) transcriptional profiling links FMO3
to RCT, (2) FMO3 knockdown reorganizes multiple processes
determining cholesterol balance, (3) FMO3 is a negative regu-
lator of nonbiliary reverse cholesterol transport, (4) FMO3 regu-
lates LXR activity to impact hepatic inflammation and ER stress,
(5) FMO3 gain of function reciprocally reorganizes intestinal
cholesterol balance and dampens hepatic inflammation, (6) the
reorganization of cholesterol balance seen with FMO3 knock-
down does not involve TMAO yet can be blocked by antibiotic-
mediated suppression of gut microbes, and (7) the hepatic
inflammation seen with FMO3 knockdown does not likely involve
either TMA or TMAO because it is not suppressed by antibiotics
or dietary TMAO. Collectively, these observations identify
transcriptional control of FMO3 as an important regulatory
switch by which cholesterol balance and hepatic inflammatory
responses are integrated.
Given that normalization of circulating TMAO levels in FMO3-
inhibited mice does not rescue the abnormal lipid and inflamma-
tory phenotype, it is likely that other FMO3 substrates or
products are involved. An obvious candidate would be the accu-
mulation of the FMO3 substrate TMA in FMO3 ASO-treated
mice. Two pieces of evidence support that TMAmay be involved
in the ability of FMO3 to regulate cholesterol balance: (1) antibi-
otic treatment, a condition that causes disappearance of circu-
lating TMA, blocks the ability of FMO3 ASO treatment to blunt
intestinal cholesterol absorption and increase fecal cholesterol
loss (Figures S4C and S4D); and (2) circulating TMA levels signif-
icantly correlate with the level of fecal neutral sterol loss (data not
shown). Although these data suggest a potential role for TMA in
regulating cholesterol balance, there is no similar support for
TMA being involved in the hepatic inflammation seen in FMO3-
inhibited mice given that antibiotic treatment does not reverse
FMO3 ASO-driven hepatic inflammation. Furthermore, the ability
of FMO3 knockdown to suppress genes involved in hepatic lipo-
genesis (FAS, ACC1, SCD1) does not involve the TMA/TMAO
axis, given that antibiotic treatment or dietary TMAO supplemen-
tation do not reverse FMO3 ASO-driven repression of these
genes (Figure S4). Collectively, these data suggest that the ability
of FMO3 inhibitors to alter cholesterol balance, inflammation,
and ER stress likely involves several molecular mechanisms
including gut microbial metabolism (alterations in cholesterol ab-
sorption and fecal neutral sterol loss) and gut microbe-indepen-
dentmechanisms (alterations in hepatic inflammation, ER stress,
and lipogenesis). Therefore, it will become increasingly impor-
tant to identify and consider all potential substrates and products
(both natural products and xenobiotics) of FMO3 that have the
potential to reorganize these diverse phenotypes. Identification
of such FMO3-regulated substrates and products could create
untapped therapeutic opportunities for lipid- or inflammation-
driven diseases.
Our discovery of FMO3 as a coordinately downregulated gene
in acute and chronic TICE models (Figure 1) lead us to hypothe-
size that FMO3 may be a key integrator of biliary and nonbiliary
RCT. To our surprise, FMO3 knockdown actually phenocopies
our chronic TICE mouse model (NPC1L1-liver-transgenic
mice), which displays severely reduced biliary cholesterol levels
with normal fecal cholesterol loss (Temel et al., 2010). Much like
NPC1L1-liver-transgenic mice (Temel et al., 2010), FMO3-in-
hibited mice seem to preferentially utilize the nonbiliary TICE
pathway for fecal disposal of cholesterol (Figure 4). In particular,
FMO3 ASO treatment strongly enhances LXR agonist-driven
macrophage RCT into the feces (Figure 4D) while at the same
time preventing LXR agonist-driven increases in biliary choles-
terol (Figure 4G). This observation is important because LXR ag-
onists preferentially stimulate the nonbiliary TICE pathway (van
der Veen et al., 2009), further supporting FMO3 as a negative
regulator of TICE. It is interesting to note that treatment with
the LXR agonist T0901317 in control ASO-treated mice signifi-
cantly reduces hepatic FMO3 mRNA (Figure 4M) and FMO3
protein (Figure 4N). These data demonstrate that now in three in-
dependent conditions where TICE is stimulated (van der Veen
et al., 2009; Temel et al., 2010; Marshall et al., 2014), FMO3 is
transcriptionally repressed (Figures 1, 4M, and 4N). Collectively,
these findings demonstrate that FMO3 gene expression is coor-
dinately repressed in several mouse models of augmented TICE
and that FMO3 knockdown promotes basal and LXR agonist-
stimulated nonbiliary RCT (Figure 4). However, it is important
to point out that since multiple steps of cholesterol balance are
altered by FMO3 knockdown, it is difficult to interpret which
step predominates to promote RCT and whether the
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reorganization of cholesterol balance seen in FMO3 knockdown
mice is derived simply from alterations in TICE. For instance, by
inhibiting cholesterol absorption (Figure 2E), FMO3 knockdown
could indirectly impact both biliary and nonbiliary macrophage
RCT rates (Sehayek and Hazen, 2008; Jakulj et al., 2010). There-
fore, although FMO3 knockdown does clearly reorganize the
biliary and nonbiliary RCT pathways toward TICE predominance,
it also alters multiple steps of forward and reverse cholesterol
transport, culminating in a net-negative cholesterol balance.
It has long been known that a complex reciprocal relationship
exists between many lipid metabolic and inflammatory path-
ways. This antagonism, collectively known as transrepression,
is orchestrated by crosstalk between several nuclear hormone
receptors (GR, PPARa, PPARg, PPARd, LXRa, NURR1, etc.)
Figure 4. FMO3 Knockdown Stimulates Nonbiliary Macrophage RCT
Female C57BL/6 mice were fed a low-cholesterol (0.02%, w/w) diet and treated with either a control (nontargeting) ASO or an ASO targeting FMO3 mRNA for
6 weeks. During the last week of treatment, mice were also orally gavaged with either a vehicle or an exogenous LXR agonist (T0901317). During the last 48 hr,
mice were singly housed, and macrophage RCT into different compartments was measured as described in Experimental Procedures.
(A) Total plasma cholesterol (TPC) levels.
(B) Time course of [3H]cholesterol accumulation in plasma.
(C) [3H]Cholesterol distribution of pooled plasma (n = 5 per pool).
(D) [3H]Cholesterol recovery in the feces.
(E) [3H]Bile acids recovery in the feces.
(F) Mass fecal neutral sterol excretion.
(G) [3H]Cholesterol recovery in gall bladder bile.
(H) [3H]Bile acids recovery in gall bladder bile.
(I) [3H]Cholesterol recovery in the liver.
(J) [3H]Bile acids recovery in the liver.
(K) [3H]Cholesterol recovery in the small intestine (SI) wall.
(L) [3H]Bile acids recovery in the small intestine (SI) wall.
(M) qPCR quantification of hepatic FMO3 mRNA levels.
(N) Western blot analysis of hepatic FMO3 protein levels.
(O) qPCR quantification of NPC1L1 mRNA levels in the duodenum.
All data represent the mean ± SEM from six to ten mice per group, and means not sharing a common superscript differ significantly (p < 0.05).
Figure 5. FMO3 Knockdown Promotes
Hepatic Inflammation and ER Stress by
Dampening LXR Activation
For dietary cholesterol-induced LXR activation
(A–C), female C57BL/6 mice were fed either a
low- (0.02%, w/w) or high-cholesterol (0.2%, w/w)
diet and treated with either a control (non-
targeting) ASO or an ASO targeting knockdown of
FMO3 for 6 weeks. For exogenous ligand-
induced LXR activation (D and E), female C57BL/
6 mice were fed a low-cholesterol (0.02%, w/w)
diet and treated with either a control (non-
targeting) ASO or an ASO targeting FMO3 mRNA
for 6 weeks. During the last week of treatment,
mice also were orally gavaged with either a
vehicle or an exogenous LXR agonist (T0901317)
as described in the macrophage RCT experi-
ments in Experimental Procedures.
(A) H&E-stained liver sections (2003 magnifica-
tion) from female C57BL/6 mice fed a low-
cholesterol (0.02%, w/w) diet and treated with
either a control ASO or an FMO3 ASO for 6 weeks.
Arrows indicate areas of localized immune cell
infiltration.
(B) Hepatic lobular inflammation score from path-
ological report. Data represent the mean ± SEM
from four mice per group; *significantly different
from the control ASO group within each diet group
(p < 0.05).
(C) qPCR quantification of genes involved in inflammation and ER stress in the liver of mice fed a low-cholesterol (L) or high-cholesterol (H) diet.
(D) qPCR quantification of genes involved in inflammation and ER stress in the liver of vehicle (V) or T0901317-treated (T) mice.
(E) Western blot analysis of FMO3, CHOP, total Src, and activated Src (p-SrcTyr416); n = 3 individual animals shown per group.
Data represent the mean ± SEM from four to eight mice per group, and means not sharing a common superscript differ significantly (p < 0.05). *Significantly
different from the control ASO group within each diet group (p < 0.05).
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and the proinflammatory master transcription factor NF-kB
(Glass and Saijo, 2010; Joseph et al., 2003; Khovidhunkit et al.,
2003). Activation of diverse nuclear hormone receptors (GR,
PPARa, PPARg, PPARd, LXRa, NURR1, etc.) can transrepress
T cell- and macrophage-driven inflammatory responses orches-
trated by NF-kB, while in a reciprocal manner, activation of NF-
kB-driven proinflammatory signaling effectively blunts nuclear
hormone receptor signaling (Glass and Saijo, 2010; Joseph
et al., 2003; Khovidhunkit et al., 2003). Relevant to our work,
LXR activation can strongly suppress NF-kB-driven cytokine
and chemokine responses to a multitude of inflammatory stimuli
(Joseph et al., 2003; Glass and Saijo, 2010). This transrepression
pathway likely underlies the hepatic inflammation and ER stress
seen with FMO3 knockdown (Figure 5). Recently, it was demon-
strated that a direct transcriptional target of LXR (LPCAT3) medi-
ates a large part of this transrepressive pathway (Rong et al.,
2013). Here, we show that FMO3 activity is a major determinant
of both LXR activation (Figure 3) and downstream anti-inflamma-
tory responses in the liver. Our data suggest that the TMA/
FMO3/TMAO pathway is a previously underappreciated regu-
lator of LXR activity, which has broad implications in sterol
balance and inflammatory processes.
Given that the link between the metaorganismal TMAO
pathway and CVD has only been established in the last 3 years,
many additional studies are required to gain insights into
where therapeutic interventions should be targeted. The studies
described here, along with previous reports linking TMAO to
CVD risk in humans (Wang et al., 2011, 2014; Tang et al., 2013;
Koeth et al., 2013), provide compelling evidence that the TMA/
FMO3/TMAO pathway is a central regulatory pathway that de-
serves further exploration. However, the ability of TMAO to pro-
mote atherosclerosis (Wang et al., 2011, 2014; Tang et al., 2013;
Koeth et al., 2013) may be mutually exclusive from the ability of
FMO3 inhibitors to reorganize cholesterol balance and hepatic
inflammation. Our studies highlight the necessity to understand
the repertoire of substrates that can be utilized by FMO3 and
also open the possibility that FMO3 may have regulatory func-
tions distinct from its enzymatic activity. Given that FMO3 knock-
down and gain of function reciprocally reorganize cholesterol
balance, inflammation, and ER stress, FMO3 is uniquely posi-
tioned among the FMO family of enzymes to impact human dis-
ease. However, further studies are warranted to determine
whether this pathway can be exploited pharmacologically in
lipid- or inflammatory-driven disease. In particular identification
of FMO3 substrates and products that play a primary role in pro-
moting nonbiliary macrophage RCT, without increasing hepatic
inflammation, would be an attractive strategy for innovative
cholesterol lowering drugs in the poststatin era. Advancement
in our understanding of the enzymology of FMO3 is thus not
only predicted to be informative in xenobiotic toxicology studies
but also may provide insights into therapeutic strategies for the
treatment or prevention of atherosclerosis.
EXPERIMENTAL PROCEDURES
Animal Studies
The acute and chronic TICE mouse models used for screening purposes have
been previously described (Marshall et al., 2014; Temel et al., 2010). For ASO-
mediated knockdown of FMO3, female C57BL/6 mice were maintained on
either low- (0.02%) or high-cholesterol (0.2%) diets for a period of 6 weeks
and simultaneously injected with control (nontargeting) or FMO3-targeting
ASOs biweekly (25 mg/kg body weight) as previously described (Marshall
et al., 2014). Macrophage RCT experiments were done as previously
described (Temel et al., 2010). All methods used for lipid biochemistry (quan-
tification of cholesterol, oxysterols, bile acids, and phospholipids) have been
previously described (Marshall et al., 2014; Koeth et al., 2013; Thomas et al.,
2013). All mice were maintained in an American Association for Accreditation
of Laboratory Animal Care-approved animal facility, and all experimental pro-
tocols were approved by the Institutional Animal Care and Use Committee at
Wake Forest University School of Medicine and the Cleveland Clinic Lerner
Research Institute.
RNA and Protein Methods
Tissue RNA extraction, real-time PCR, and microarray analyses were per-
formed as previously described (Thomas et al., 2013; Marshall et al., 2014).
Immunoblotting was conducted as previously described (Thomas et al.,
2013). A detailed description of RNA and protein methods is available in
Supplemental Experimental Procedures.
Statistical Analysis
Most data are expressed as the mean ± SEM and were analyzed using either a
one-way or a two-way ANOVA followed by Student’s t tests for post hoc anal-
ysis using JMP version 5.0.12 software (SAS Institute). Formicroarray analysis,
we used empirical Bayes method implemented in R package limma (Smyth
2004).
ACCESSION NUMBERS
The GEO accession number for the data reported in this paper is GSE64326.
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Supplemental Information includes Supplemental Experimental Procedures,
five figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.12.036.
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